Search Results - "O'Malley, Tyler"

Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases by Erkan, Doruk, Vega, Joann, O'Malley, Tyler, Concoff, Andrew

“…The objective of this study was to analyze complement activation in antiphospholipid antibody (aPL)-positive patients without other systemic autoimmune…”
Get full text

Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d by Sciascia, Savino, Bloch, Rory, O’Malley, Tyler, Kammesheidt, Anja, Alexander, Roberta Vezza

“…Background Classification criteria for antiphospholipid syndrome (APS) require that antiphospholipid antibody (aPL) positivity is confirmed after at least 12…”
Get full text

Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients by Qu, Ying, Brady, Kelley, Apilado, Robert, O’Malley, Tyler, Reddy, Smitha, Chitkara, Puja, Ibarra, Claudia, Alexander, Roberta Vezza, Dervieux, Thierry

“…[Display omitted] •VAMS was successfully applied for the first time to the therapeutic drug monitoring of HCQ in rheumatoid arthritis patients.•LC–MS/MS…”
Get full text

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus by O’Malley, Tyler, Xie, Fenglong, Su, Yujie, Clinton, Cassie, Zack, Debra J, Haechung, Chung, Grabner, Michael, Curtis, Jeffrey R

Get full text

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus by Dervieux, Thierry, Conklin, John, Ibarra, Claudia, O’Malley, Tyler, Bentow, C., Mahler, Michael, Aure, Mary Ann R.

“…Objective. We sought to evaluate different anti-double-stranded DNA assays for their performance characteristics in monitoring disease activity fluctuations in…”
Get full text

Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study by Balevic, Stephen, Sun, Kai, Rogers, Jennifer L, Eudy, Amanda, Sadun, Rebecca Eli, Maheswaranathan, Mithu, Doss, Jayanth, Criscione-Schreiber, Lisa, O'Malley, Tyler, Clowse, Megan, Weiner, Daniel

“…ObjectiveCharacterise the relationship between hydroxychloroquine (HCQ) blood levels and the number of missed doses, accounting for dosage, dose timing and the…”
Get full text

Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases by Brady, Kelley, Qu, Ying, Stimson, Deborah, Apilado, Robert, Vezza Alexander, Roberta, Reddy, Smitha, Chitkara, Puja, Conklin, John, O'Malley, Tyler, Ibarra, Claudia, Dervieux, Thierry

“…Abstract Objective Methotrexate (MTX) polyglutamate (MTXPG3) levels from isolated red blood cells (RBCs) collected by venipuncture have clinical utility in…”
Get full text

Cell-bound complement activation products associate with lupus severity in SLE by Arriens, Cristina, Alexander, Roberta Vezza, Narain, Sonali, Saxena, Amit, Collins, Christopher E, Wallace, Daniel J, Massarotti, Elena, Conklin, John, Kalunian, Kenneth C, Putterman, Chaim, Ramsey-Goldman, Rosalind, Buyon, Jill P, Askanase, Anca, Furie, Richard A, James, Judith A, Bello, Ghalib A, Manzi, Susan, Ahearn, Joseph, O'Malley, Tyler, Weinstein, Arthur, Dervieux, Thierry

“…ObjectivesTo evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and…”
Get full text

1802 CAPSTONE: an observational retrospective analysis comparing a complement activation multianalyte panel vs. Standard ANA testing: systemic lupus erythematosus diagnosis, treatment outcomes and economic impact by O’Malley, Tyler, Xie, Fenglong, Su, Yujie, Clinton, Cassie, Zack, Debra J, Haechung, Chung, Grabner, Michael, Curtis, Jeffrey R

“…BackgroundSystemic Lupus Erythematosus (SLE) is a complex clinical disease that often takes years and repeated testing to adequately diagnose. Standard…”
Get full text

303 Clinical and laboratory associations of longitudinal cell-bound complement activation products in SLE by Rogers, Jennifer L, Eudy, Amanda M, Wojdyla, Daniel, O’Malley, Tyler, Pisetsky, David S, Criscione-Schreiber, Lisa G, Sun, Kai, Sadun, Rebecca E, Maheswaranathan, Mithu, Doss, Jayanth, Alexander, Roberta Vezza, Clowse, Megan EB

“…IntroductionCell-bound complement activation products (CB-CAPs) in a multi-analyte assay with algorithm (MAP) is a valuable biomarker for the diagnosis of SLE…”
Get full text

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus by Ramsey‐Goldman, Rosalind, Alexander, Roberta Vezza, Massarotti, Elena M., Wallace, Daniel J., Narain, Sonali, Arriens, Cristina, Collins, Christopher E., Saxena, Amit, Putterman, Chaim, Kalunian, Kenneth C., O'Malley, Tyler, Dervieux, Thierry, Weinstein, Arthur

“…Objective To evaluate the frequency of cell‐bound complement activation products (CB‐CAPs) as a marker of complement activation in patients with suspected…”
Get full text

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE by Petri, Michelle A, Conklin, John, O'Malley, Tyler, Dervieux, Thierry

“…BackgroundLow C3 and lupus anticoagulant (LAC) are known risk factors for thrombosis in SLE. We evaluated the association between C4d products deposited on…”
Get full text

1304 Factors in lupus diagnosis by McClamb, Daria, Oberholtzer, Lydia, Marion, Ashley, Topf, Lauren, Crimmings, Mary, Tse, Karin, Wegener, John, Melucci, Valerie, O’Malley, Tyler, Zack, Debra, Thomas, Donald E

“…BackgroundLupus is a complex, chronic autoimmune disease affecting an estimated 1.5 million Americans.Lupus symptoms are heterogeneous. Suboptimal diagnostic…”
Get full text

Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus by Dervieux, Thierry, Conklin, John, Ligayon, Jo-Anne, Wolover, Leilani, O'Malley, Tyler, Alexander, Roberta Vezza, Weinstein, Arthur, Ibarra, Claudia A.

“…We describe the analytical validation of an assay panel intended to assist clinicians with the diagnosis of systemic lupus erythematosus (SLE). The…”
Get full text

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements by Putterman, Chaim, Furie, Richard, Ramsey-Goldman, Rosalind, Askanase, Anca, Buyon, Jill, Kalunian, Kenneth, Chatham, W Winn, Massarotti, Elena, Kirou, Kyriakos, Jordan, Nicole, Blanco, Irene, Weinstein, Arthur, Chitkara, Puja, Manzi, Susan, Ahearn, Joseph, O'Malley, Tyler, Conklin, John, Ibarra, Claudia, Barken, Derren, Dervieux, Thierry

“…Objective To compare the performance characteristics of cell-bound complement (C4d) activation products (CBCAPS) on erythrocyte (EC4d) and B cells (BC4d) with…”
Get full text

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE by Wallace, Daniel J, Alexander, Roberta Vezza, O'Malley, Tyler, Khosroshahi, Arezou, Hojjati, Mehrnaz, Loupasakis, Konstantinos, Alper, Jeffrey, Sherrer, Yvonne, Fondal, Maria, Kataria, Rajesh, Powell, Tami, Ibarra, Claudia, Narain, Sonali, Massarotti, Elena, Weinstein, Arthur, Dervieux, Thierry

“…ObjectiveWe compared the physician-assessed diagnostic likelihood of SLE resulting from standard diagnosis laboratory testing (SDLT) to that resulting from…”
Get full text